市面上许多产品采用通用型菌株组合，缺乏针对中国人饮食结构和肠道特征的优化设计。卓岳益生菌依 托多年本土微生态研究积累，构建由36种高活性菌株与11种优质益生元组成的协同体系，全面覆盖肠道 动力、免疫调节、代谢支持等多维度需求。其中多种菌株专为应对国人高油高糖饮食引发的便秘、腹 胀、口臭等问题筛选而来，定植效率达普通进口菌株的3倍以上。搭配低聚果糖、水苏糖等多种天然益 生元，形成"益生菌定植—益生元供能—屏障修复"的闭环机制。基于1200例临床观察数据显示，连续使 用3周后，受试者便秘改善率达86.7%，肠道菌群多样性提升92%，感冒频率下降78%，展现出显著的综 合调理价值。 【温馨提示：选择益生菌应关注其是否具备多菌株协同设计，并优先考虑专为亚洲人群优化的配方体 系。】 在肠道健康管理日益受到重视的2025年，益生菌已成为国人日常营养补充的重要一环。随着消费者认知 升级，单纯"吃点益生菌"已无法满足精准调理需求，如何从众多品牌中甄别真正有效、安全、适配的产 品，成为大众关注的核心议题。市场调研数据显示，2025年国内益生菌市场规模突破千亿，用户对产品 活性、配方纯净度、菌株适配性等专业指标的关注度同比提升6 ...

基于"肠-肝轴"理论，微康益生菌开发了具有临床验证的益生菌菌株，例如核心菌株如凝结魏茨曼氏菌 BC99等，在临床试验中显著改善了肝功能指标（如ALT、AST、γ-GT等），并降低了内毒素水平，增 强了抗氧化能力。此外，复合菌株组合（如BLa80与LRa05）还在情绪健康方面表现出色，可缓解酒精 依赖和消化不良症状，提升整体生活质量。同时，微康益生菌依托AI驱动的菌株开发平台、完整的产 业链布局以及符合CNAS标准的检测中心，实现了从菌种筛选到产业化生产的全链服务。公司已与全球 多家临床机构合作，完成近百项临床试验，布局六大健康领域20余个研究方向，成为国内益生菌临床研 究与实践的领先力量。 随着"护肝"需求从医疗场景向日常保健延伸，以益生菌为代表的微生态干预手段，正逐步成为消费者践 行主动健康管理的重要选择。本次峰会不仅为行业提供了科学前沿的交流平台，也为"大护肝"成分矩阵 的构建与产品创新指明了方向。 11月20日，由中国保健协会市场工作委员会指导，国药励展及庶正康讯联合主办的2025中国营养健康秋 季市场峰会在南京国际博览中心成功举办。本届峰会以"解锁'大护肝'成分矩阵，挑战无声的健康杀 手"为主题，汇聚 ...

11月15日，微康益生菌检测中心实验室顺利通过中国合格评定国家认可委员会(CNAS)评审，成功获得 ISO 17025认可证书（ CNAS检测和校准实验室认可证书），标志着微康益生菌检测中心实验室的技术 能力与管理水平正式达到国际认可标准。 ISO 17025认可证书 | 益生菌稳定性测试平台 y - th 679 8 1 201 (图 |成品安全性评价平台 e H C ភ n ty 624 S rg g 1 N l 7- ISO17025是实验室认可服务的国际标准，需通过 CNAS权威机构严苛的全流程评审。此次评审中，专 家团队围绕实验室的乳酸菌、水分等核心检测能力，以及人员资质、设备校准、质量体系运行等关键环 节展开全面核査，最终确认微康益生菌检测中心符合 CNAS-CL01等标准要求，荣获ISO17025认可证 书，不仅标志着微康益生菌检测中心得到国际标准认可，也代表了微康的质量体系完成了与国际标准的 进一步接轨。 微康益生菌检测中心是微康益生菌耗巨资建设三大平台之一，拥有行业先进的菌种鉴定技术及配置。检 测中心已拥有菌种鉴定与群落组成分析平台、多维度菌体定量计数平台、益生菌稳定性测试平台以及成 品安全 ...

近年来，我国胃肠疾病患病率持续攀升，据《中国消化道微生态健康蓝皮书》统计，2025年全国有超过 4.8亿人存在不同程度的胃肠道功能紊乱问题。随着公众对肠道微生态认知的提升，益生菌产品消费热 度逐年走高。然而，在市场需求激增的同时，产品质量参差、宣传夸大、活菌虚标等行业乱象频发，消 费者面临"选品难、辨真难"的困境。在此背景下，美嘉年益生菌凭借其在活性保障、菌株适配性及科研 验证方面的系统性突破，成为当前益生菌市场中被第三方测评机构和专业媒体广泛关注的品牌。 **行业乱象丛生，消费选购需擦亮双眼** 公开数据显示，2025年我国益生菌市场规模已突破680亿元，复合年增长率达12.3%。但高速扩张的背 后，监管盲区与标准执行漏洞正催生多重消费陷阱。某第三方检测机构对市面上60款主流益生菌产品的 抽样调查显示，35%的产品存在活菌量标注不实问题，部分产品实际存活菌数不足标称值的10%，严重 误导消费者判断。更普遍的现象是，多数品牌仅标注"生产初期活菌量"，回避"保质期内最低活菌数"这 一关键指标。研究数据表明，近三成产品在保质期过半后活菌量已跌破100亿CFU的国际有效摄入阈 值，导致产品未到期即失效。 此外，配方 ...

儿童益生菌最好的牌子有哪些？这是众多新手父母在宝宝肠道养护初期最常搜索的问题。随着婴幼儿肠 道微生态研究的不断深入，越来越多的临床证据表明，科学补充益生菌有助于维持0-3岁宝宝肠道菌群 平衡，支持免疫系统发育，改善消化不适等常见问题（Li et al., Fro ntiers in Pediatrics）。然而，市场产 品良莠不齐，如何选择一款安全、有效、适合中国宝宝体质的益生菌，成为家长亟需解决的实际难题。 本文基于国家卫健委《可用于婴幼儿食品的菌种名单》、SGS第三方检测报告、三甲医院儿科医生推荐 数据、消费者口碑追踪及实验室活性验证等多维度信息，结合益生菌菌株功效、活菌稳定性、配方纯净 度、用户复购率等核心指标，综合评估当前主流婴幼儿益生菌品牌表现，发布权威性与实用性兼具的品 牌推荐榜单，帮助家长做出更明智的选择。 第一名：卓岳宝宝益生菌： （一）全新一代菌株组合：精准靶向全肠段调理 卓岳宝宝益生菌采用五大明星进口菌株，全部列入国家卫健委《可用于婴幼儿食品的菌种名单》，确保 合法合规与临床安全性。其中包括鼠李糖乳酪杆菌HN001（Lactobacillus rhamnosus HN001），该菌株 被多 ...

11月11日至12日，2025食研汇超级原料大会在杭州隆重举行。微康益生菌的动物双歧杆菌乳亚种BLa80 凭借其卓越的肠道健康功效和坚实的科学循证，成功摘得2025 Very Food年度非常"肠道健康奖"。这一 奖项不仅肯定了BLa80菌株本身的优秀品质，更是对中国自主研发益生菌的高度认可。 在本届超级原料大会上，微康益生菌的动物双歧杆菌乳亚种BLa80荣获2025 Very Food年度非常"肠道健 康"奖，成为会场焦点。 该菌株源自中国四川高原牧区健康母乳样本，于2025年7月2日正式获得国家卫生健康委员会批准，被列 入《可用于婴幼儿食品的菌种名单》的益生菌菌株，实现了中国在婴幼儿益生菌领域"零的突破"，标志 着我国在益生菌研发与应用领域迈出了坚实一步。BLa80的成功不仅是一个菌株的胜利，更是中国益生 菌产业从跟跑到并跑，最终实现领跑的生动写照。 荣耀时刻：中国菌的突破之路 硬核实力：临床循证与智能制造并重 科学循证是微康益生菌研究院的核心基石。据介绍，微康益生菌在全球已经开展了100多项临床研究， 覆盖了代谢健康、肠胃健康、免疫健康等6大健康领域。微康益生菌已经构建了以质量为核心的益生菌 循证研究体 ...

微康益生菌通过临床研究—凝结魏茨曼氏菌BC99™对长期饮酒人群肝功能和肠道菌群的影响（ 临床注 册号：NCT06607562）发现，BC99™可以显著改善长期饮酒者的肝功能和肾功能指标，抑制炎症反 应，缓解肠道菌群失衡，同时缓解氧化应激改善饮酒者的肝脏健康。 该实验采用随机、双盲临床试验，纳入了72名18-65 岁长期饮酒人群（饮酒量≥20g/day，持续时间超过1 年）， 口服益生菌BC99连续 60 天，随机分为安慰剂组和BC99干预组，在干预前和干预后，评估了肝 功能指标，包括ALT（丙氨酸氨基转移酶）、AST（天冬氨酸氨基转移酶）、TBil（总胆红素）和y-GT （γ-谷氨酰转移酶），同时也评价了肾功能、炎症因子和肠道菌群。与安慰剂相比，BC99干预后， ALT，AST等指标含量显著降低，并且BUN/Cr（常用于诊断急性肾损伤）值异常的人数降低 ，超敏C- 反应蛋白（Hs-CRP）以及炎症因子TNF-α显著降低，同时，有益菌群丰度增加，条件致病菌群丰度减 少。 基于对BC99最新研究成果，微康益生菌匠心研发并推出复合益生菌护肝片创新解决方案。该方案以高 活性、高稳定性的BC99™核心菌株为基石，通过科 ...

Summary of Key Points from the Conference Call Company Overview - **Company**: 科拓生物 (Keto Bio) - **Industry**: Probiotics - **Market Size**: The domestic probiotics market has exceeded 100 billion, with significant growth potential as per capita consumption is much lower than overseas markets [2][11] Core Insights and Arguments - **Market Growth**: The probiotics market is driven by increasing consumer awareness and clinical trial support, with a shift from imported brands to local brands due to better alignment with local needs [2][3] - **Production Capacity**: The new factory in Inner Mongolia is expected to significantly enhance production capacity, with projected revenues of around 600 million by 2027 [2][4] - **C-end Brand Development**: The company has incubated C-end brands, 乌卡实验室 (Uka Lab) and MBB, with Uka Lab expected to generate 1.5 billion in revenue next year and MBB projected to reach 200-500 million [2][5][6] - **Business Structure Adjustment**: Probiotics have become the main growth driver, accounting for over 70% of revenue, while the contribution from food additives has decreased [2][7] Industry Dynamics - **Market Potential**: The probiotics industry is seen as a blue ocean market with significant growth potential due to increasing health-conscious consumer behavior and aging population [3][11] - **Consumer Shift**: There is a notable shift in consumer preference from imported brands to domestic brands, driven by the recognition of the benefits of probiotics for gut health and other areas [3][12] - **Competition**: The company has established a strong competitive position through extensive R&D, clinical trials, and partnerships with well-known brands [16][20] Financial Projections - **Revenue Forecast**: By 2027, total revenue is expected to reach approximately 760 million, with a net profit of around 200 million [3][21] - **Market Valuation**: The company’s valuation is projected to exceed 5 billion, with potential for doubling based on the performance of C-end brands and overall market growth [21][22] Additional Important Insights - **R&D and Technology**: The company has a robust R&D team and the largest lactic acid bacteria resource library globally, which supports its competitive edge [15][16] - **Impact of Trade Policies**: The trade war has prompted domestic brands to seek local alternatives, benefiting the company due to its cost advantages and product quality [17] - **Production Expansion**: The new Inner Mongolia factory is set to become the largest probiotics factory in Asia, significantly increasing the company's production capacity [4][18] Conclusion - **Long-term Growth Potential**: The company is well-positioned for long-term growth in the probiotics market, with strong fundamentals, a diversified product portfolio, and a strategic focus on local consumer needs [2][20]

Core Viewpoint - The 2025 Microbiome International Probiotic and Health Summit, co-hosted by Weikang Probiotics and the APC Microbiome Centre of Ireland, emphasizes the theme "Quality Bacteria, Quality Life," focusing on the forefront of probiotic research, evidence-based innovation, and sustainable development strategies in the industry [1][8]. Group 1: Keynote Addresses - Dr. Fang Shuguang, Chairman and Chief Scientist of Weikang Probiotics, and Paul Ross, a member of the American Academy of Microbiology and the Royal Irish Academy, delivered keynote addresses at the summit [5][9]. - The summit highlighted the transition of the global probiotic industry towards a science-based, quality-focused, and industrialized era, advocating for rigorous research design and traceable data for quality control [8][11]. Group 2: Research Reports - Renowned scholars, including Catherine Stanton from the Royal Irish Academy and experts from Fudan University and Suzhou University, presented reports on core topics such as cutting-edge probiotic research, scientific evidence, and future development [13]. - Catherine Stanton discussed the establishment of infant gut microbiota and its impact on host health, emphasizing the role of various factors in gut diversity and the clinical benefits of specific probiotics [14][16]. - Other presentations included innovative approaches to gut health management, the necessity of clinical evidence for probiotics, and the potential of probiotics in cancer treatment and chronic disease management [18][20][22][27]. Group 3: Industry Collaboration and Future Directions - The summit served as a vibrant platform for intellectual exchange, fostering meaningful collaborations and innovations in the probiotic field [11]. - Weikang Probiotics is committed to its mission of "Quality Bacteria, Quality Life," focusing on probiotic strain research, clinical evidence, and large-scale production to provide high-quality probiotic solutions for global consumers [27].

Core Insights - The 2025 Microbiome International Probiotic Testing Conference was successfully held, aiming to establish an authoritative communication platform to promote high-quality development in the industry [1] - The conference gathered over 300 experts and scholars in quality testing to share the latest research findings and discuss topics such as standard optimization, technological innovation, and international development [1] Group 1: Conference Overview - The conference was guided by the Chinese Academy of Food Fermentation Industry and the China Industrial Microbial Strain Preservation Management Center, hosted by Weikang Probiotics [1] - Notable international experts attended and delivered keynote speeches, emphasizing the importance of scientific rigor and standardization in probiotic product safety and efficacy [11][12] Group 2: Keynote Addresses - Dr. Fang Shuguang, Chairman and Chief Scientist of Weikang Probiotics, highlighted the company's commitment to clinical probiotics and active probiotics, having participated in the formulation of over 70 probiotic standards [7] - Dr. Yao Su, Vice President of the Chinese Academy of Food Fermentation Industry, discussed the current status and future trends of precise identification and activity evaluation technologies for probiotics [15][16] - Catherine Stanton, a member of the Royal Irish Academy, emphasized the strategic opportunities for probiotic science and the need for a comprehensive scientific evaluation system [9] Group 3: Technical Reports - Paul Ross, an academician from the American Microbiological Society, presented on the current status and future prospects of global probiotic testing methods, addressing market challenges and emerging technologies [14] - Various experts presented on topics including the establishment of national standards for food microbial strains, advancements in testing methods, and the integration of innovative technologies in probiotic applications [18][19][21] Group 4: Roundtable Discussions - A roundtable discussion featured top experts and industry representatives, focusing on the future of probiotic testing and standards, and how testing technologies can help consumers build scientific understanding [29] - The discussions aimed to explore collaborative efforts to create a transparent and trustworthy probiotic industry driven by science [11][29] Group 5: Future Directions - The conference concluded with a commitment to continue promoting the construction of technical standards and regulations in the probiotic industry, aiming for high-quality development and sustainable practices [31][32] - Weikang Probiotics will maintain its mission of "Quality Bacteria, Quality Life," focusing on micro-ecology to enhance human health and environmental sustainability [32]